StreetInsider.com News Articles

Roth/MKM Starts CapsoVision Inc (CV) at Buy

Fri, 28 Aug 2026 07:07:29 -0400

Roth/MKM analyst Kevin Holder initiates coverage on CapsoVision Inc (NASDAQ: CV) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on CapsoVision Inc click here. For more ratings news on CapsoVision Inc click here.

Shares of CapsoVision Inc closed at $6.06 yesterday.

Titan Partners Starts CapsoVision Inc (CV) at Buy

Wed, 26 Aug 2026 07:05:00 -0400

Titan Partners initiates coverage on CapsoVision Inc (NASDAQ: CV) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on CapsoVision Inc click here. For more ratings news on CapsoVision Inc click here.

Shares of CapsoVision Inc closed at $5.85 yesterday.

Form EFFECT CapsoVision, Inc

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963773.html

Form EFFECT CapsoVision, Inc

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963773.html

Form 424B5 CapsoVision, Inc

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961813.html

Form 424B5 CapsoVision, Inc

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961813.html

Form 8-K CapsoVision, Inc For: Aug 13

Tue, 18 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26939906.html

Form 8-K CapsoVision, Inc For: Aug 13

Tue, 18 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26939906.html

CapsoVision (CV) Reiterated at Speculative Buy by Benchmark

Fri, 14 Aug 2026 08:00:47 -0400

Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating and $10.00 price target on CapsoVision Inc (NASDAQ: CV).

The analyst commented, "CapsoVision provided a 2Q update. Since launch, CapsoCam Plus has now been used in more than 176,000 procedures (up from 167,000 last quarter). Expectations for US FDA 510(k) clearance of the AI assisted reading feature for CapsoCam Plus slipped to the end of 3Q but the product will likely contribute to 4Q results. The European launch is starting now, and management remains encouraged by customer interest in the product. The 510(k) submission for CapsoCam Colon is now anticipated during 4Q

CapsoVision (CV) files $250M mixed shelf

Thu, 13 Aug 2026 16:54:11 -0400

CapsoVision (NASDAQ: CV) file $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Warrants
Rights
Units

CapsoVision (CV) files $250M mixed shelf

Thu, 13 Aug 2026 16:54:11 -0400

CapsoVision (NASDAQ: CV) file $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Warrants
Rights
Units

Form S-3 CapsoVision, Inc

Thu, 13 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26922318.html

Form S-3 CapsoVision, Inc

Thu, 13 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26922318.html

Form 10-Q CapsoVision, Inc For: Jun 30

Thu, 13 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26922008.html

Form 10-Q CapsoVision, Inc For: Jun 30

Thu, 13 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26922008.html

CapsoVision sets up $100M at-the-market stock offering via Cantor

Thu, 13 Aug 2026 16:15:02 -0400

CapsoVision, Inc. (NASDAQ: CV) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. on August 13, 2026, establishing an at-the-market offering program under which the company may sell up to $100,000,000 in shares of its common stock.

Under the agreement, CapsoVision will set the parameters for any share sales, including the number of shares to be issued, the time period for sales, daily volume limits, and any minimum price thresholds. Cantor will act as sales agent or principal, selling shares on the Nasdaq Capital Market or other trading venues, using methods that qualify as at-the-market offerings under

CapsoVision sets up $100M at-the-market stock offering via Cantor

Thu, 13 Aug 2026 16:15:02 -0400

CapsoVision (CV) Misses Q2 EPS by 4c

Thu, 13 Aug 2026 16:11:05 -0400

CapsoVision (NASDAQ: CV) reported Q2 EPS of ($0.15), $0.04 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.6 million.

For earnings history and earnings-related data on CapsoVision (CV) click here.

Form 8-K CapsoVision, Inc For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920978.html

Form 8-K CapsoVision, Inc For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920978.html

CapsoVision Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:05:00 -0400

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.

Recent Highlights

Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.
CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.
Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small

CapsoVision Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:05:00 -0400

Recent Highlights

Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.
CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.
Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small

CapsoVision Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:05:00 -0400

Recent Highlights

Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.
CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.
Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small

CapsoVision Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:05:00 -0400

Recent Highlights

Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.
CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.
Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small

CapsoVision launches AI Highlights for capsule endoscopy internationally

Mon, 03 Aug 2026 16:31:01 -0400

CapsoVision, Inc. (NASDAQ: CV) has announced the international launch of AI Highlights, an AI-assisted feature for its CapsoCam Plus capsule endoscopy system, including availability in the European Union under the Medical Device Regulation (MDR).

AI Highlights is integrated within CapsoView, CapsoVision's video processing and review software. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and flags frames with suspected clinically relevant findings for physician review. Processed videos can be reviewed within CapsoView or through the company's cloud-based CapsoCloud platform, depending on workflow configuration.

"The international launch of AI Highlights reflects our continued focus on developing integrated